RECEIVED CENTRAL FAX CENTER

Law Offices of Albert Wai-Kit Chan, LLC

OCT 1 9 2006

World Ploza, Suite 604, 141-07 20th Avenue • Whitestone, NY 11357 Tel: (718) 799-1000• Fax: (718) 357-8615 e-mail: chank@kitchanlaw.com

PL	EASE DELIVER THE FOLLOWING PAGES	•
	UNITED STATES PATENT AND TRADEMARK	OFFICE

COMPANY ;

UNITED STATES PATENT AND TRADEMARK OFFICE

FAX NO.

(571) 273-8300

FROM

TO

ALBERT WAI-KIT CHAN/ah

U.S. SERIAL NO.

10/593,217

RE

KING et al., for COMBINATION THERAPY COMPRISING CLORETAZINETM, U.S. Serial No. 10/593,217, filed September 15, 2006, National Stage Application of International Application No. PCT/US2005/010152, filed March 25, 2005, which claims priority of U.S. Serial No. 60/556,565, filed March 26, 2004 – Our Dkt #891-A-

PCT-US

JOTAL NUME	BER OF PAGES,	, INCLUDING COVER SHEET:	10	
DATE	:	October 19, 2006		

* IF YOU DO NOT RECEIVE ALL THE PAGES, PLEASE CALL BACK AS SOON AS POSSIBLE TO (718) 799-1000.

Message

Applicant

: KING, et al.

File No.: 891-A-PCT-US

Client

: Vion Pharmaceuticals, Inc.

Date

: October 19, 2006

Please see the attached Information Disclosure Statement for the above-identified application.

I hereby certify that the enclosed paper is being facsimile transmitted to: United States Patent and Trademark Office, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 at (571) 273-8300 on the date shown below.

Albert Wai-Kit Chan

Date

Reg. No. 36,479

THE INFORMATION CONTAINED IN THIS FACSIMILE TRANSMISSION IS INTENDED SOLELY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE DESIGNATED RECIPIENT(S) NAMED ABOVE, THIS TRANSMISSION MAY CONTAIN INFORMATION THAT IS CONFIDENTIAL UNDER THE CLIENT AND ATTORNEY RELATIONSHIP. IF THE READER OF THIS MESSAGE IS NOT A DESIGNATED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO A DESIGNATED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRUCTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, OR IF UPON READING THIS DOCUMENT YOU HAVE REASON TO BELIEVE THAT THE DOCUMENT WAS ENADVERTENTLY SENT TO YOU, PLEASE NOTIFY US IMMEDIATELY BY COLLECT TELEPHONE CALL AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Dkt #891-A-PCT-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED CENTRAL FAX CENTER

Applicants

: King, et al.

OCT 1 9 2006

U.S. Serial No. : 10/593,217, National Stage Application of International Application PCT/US2005/010152, filed March 25, 2005, claiming priority of U.S. Serial

No.60/556,565, filed March 26, 2004

Filed

: September 15, 2006

For

: COMBINATION

THERAPY COMPRISING

CLORETAZINE™

Law Offices of Albert Wai-Kit Chan, LLC

World Plaza, Suite 604 141-07 20th Avenue Whitestone, NY 11357

October 19, 2006

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, Applicants would like to direct the Examiner's attention to the following references which are listed below and on Form PTO/SB/08B (which is attached hereto as Exhibit A), and further attached as Exhibits 1 (4 pages)

1. PCT International Preliminary Report on Patentability for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152, Filed March 25, 2005, Dated September 26, 2006 [Exhibit 1]

Applicants : KING, et al. U.S. Serial No. : 10/593,217

Filing Date : September 15, 2006

Page : 2

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of the Information Disclosure Statement. However, if additional fees are required, authorization is given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

I hereby certify that this paper is being facsimile-transmitted to:

Commissioner for Patents
P.O. Box 1450

10/19/06

Date

Alexandria, VA 22313-1450

Albert Wai Kit Chan

Reg. No. 36,479

allero wai kit Caa

Albert Wai-Kit Chan
Registration No. 36,479
Attorney for Applicant(s)
Law Offices of
Albert Wai-Kit Chan, LLC
World Plaza, Suite 604
141-07 20th Avenue
Whitestone, New York 11357

Tel: (718) 799-1000 Fax: (718) 357-8615

E-mail: chank@kitchanlaw.com

Exhibit A

RECEIVED **CENTRAL FAX CENTER**

OCT 1 9 2006

PTO/SE/08B (02-03)
Approved for use through 04/30/2003, OMB 0651-0031
U.S. Petent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1448/PTQ .	re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
	Application Number	10/593,217	
INFORMATION DISCLOSURE	Filing Date	September 15, 2006	
STATEMENT BY APPLICANT	First Named Inventor	King, et al.	
(Use as many sheets as necessary)	Art Unit	Not Yet Known	
,	Examiner Name	Not Yet Known	
Sheet 1 of 1	Attorney Docket Number	891-A-PCT-US	

Examiner	Cite	OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	,
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	PCT International Preliminary Report on Patentability for VION Pharmaceuticals, et al., Int'l Application No. PCT/US2005/010152, Filed March 25, 2005, Dated September 26, 2006	
			_

Examiner		Date	
Cianat		Date	ž
Signature		Considere	d
*FYAMINER: I	Hint If minman and an ideas whether we have		,

*EXAMINER: Initial if reference considered, whether or not distion is in conformance with MPEP 609. Draw line through distion if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicent's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is stacked. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a betraft by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 3 CFR 1.14. This collection is estimated to take 120 minutes to complete, including satisfing, propering, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time, you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commission, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

If you need assistance in completing the form, cell 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Exhibit 1